BioSpace News Archive

Portola Pharmaceuticals, Inc.® announced that it will host a webcast and conference call to discuss the Company’s financial results for the quarter ended March 31, 2020, and provide a general business overview, on Monday, May 11, 2020, at 4:30 p.m. ET..

The Human Vaccines Project, a global nonprofit consortium is launching the COVID Vaccine Initiative, with the goal to ensure the development of safe, effective, accessible vaccines for those most vulnerable to COVID-19.

Agastiya Biotech LLC (www.agastiyabiotech.com) today announces it has discovered its previously tested anti-cancer small molecule AB001 as a viable SARS-CoV-2 virus therapeutic.

Emergent BioSolutions Inc. (NYSE:EBS) today announced an agreement whereby Emergent will deploy its contract development and manufacturing (CDMO) services to support the manufacturing of Johnson & Johnson’s lead vaccine candidate for COVID-19 that leverages the AdVac® and PER.C6® technologies from the Janssen Pharmaceutical Companies of Johnson & Johnson.

First in Series of Anticipated Strategic Collaborations Designed to Further the Company’s Goal of Ensuring Global Supply of a Safe and Effective Vaccine for COVID-19

Chardan Healthcare Acquisition 2 Corp. (NYSE American: CHAQ.U, the “Company”) announced today that it priced its initial public offering of 8,500,000 units at $10.00 per unit. The units are expected to be listed on NYSE American (“NYSE”) and trade under the ticker symbol “CHAQ.U” beginning April 24, 2020.

IBM Business Partner Evanston Technology Partners and Cylera, recently partnered together to address new challenges facing hospitals, providing asset management and cybersecurity protection, through a newly formed joint Healthcare Asset Operations Center (HAOC) solution that provides healthcare delivery organizations a way to continuously manage, optimize, and secure critical medical devices, including ventilators and supporting healthcare assets such as IoT,

ORIC Pharmaceuticals, Inc. (NASDAQ: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced the pricing of its initial public offering of 7,500,000 shares of its common stock at a price to the public of $16.00 per share.

Grants Distributed to Four Non-Profit Organizations Serving Patients, Healthcare Workers and Their Families Dealing with the Impact of COVID-19